AstraZeneca Annual Report and Financial Statements Form 20-F Information 2003 87 22 Net cash inflow from trading operations 2003 2002 2001 $m $m $m Operating profit before exceptional items 4,111 4,356 4,156 Depreciation and amortisation 1,290 960 860 Stocks increase decrease 131 101 417 Debtors increase decrease 540 198 138 Creditors increase decrease 430 402 727 Other non-cash movements 317 65 120 4,617 5,686 4,130 23 Cash flows related to exceptional items Current period cash flow related to exceptional items and merger 2003 2002 2001 related payments, before associated tax charge relief $m $m $m Synergy and integration costs 25 68 312 Zoladex OIG settlement 355 Costs relating to disposals and demerger of other businesses 11 25 56 Outflow related to exceptional items 391 93 368 Proceeds from disposal of fixed assets accounted for as exceptional 10 Exceptional items cash flow 391 93 358 24 Acquisitions of subsidiaries and purchases of minority interests There were no significant business acquisitions in any of the years presented.
All acquisitions have been accounted for by the purchase method of accounting.
2003 2002 2001 Total Total Total fair fair fair value value value $m $m $m Fixed assets 4 Current assets 26 Creditors due within one year 16 Provisions for liabilities and charges 1 Fair value of net assets acquired 13 Goodwill acquired 41 Consideration for subsidiaries and operations acquired 54 Purchases of minority interests 7 47 Less: Cash included in undertaking acquired 3 Net cash consideration 44 Assets and liabilities were adjusted to their fair values based on external valuations and internal assessments.
There were no significant differences between book and fair values in respect of the acquisitions made.
